Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

PURPOSE: Pembrolizumab monotherapy has shown antitumor activity in patients with small-cell lung cancer (SCLC). The randomized, double-blind, phase III KEYNOTE-604 study compared pembrolizumab plus etoposide and platinum (EP) with placebo plus EP for patients with previously untreated extensive-stag...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Rudin, Charles M., Awad, Mark M., Navarro, Alejandro, Gottfried, Maya, Peters, Solange, Csőszi, Tibor, Cheema, Parneet K., Rodriguez-Abreu, Delvys, Wollner, Mirjana, Yang, James Chih-Hsin, Mazieres, Julien, Orlandi, Francisco J., Luft, Alexander, Gümüş, Mahmut, Kato, Terufumi, Kalemkerian, Gregory P., Luo, Yiwen, Ebiana, Victoria, Pietanza, M. Catherine, Kim, Hye Ryun
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2020
Sujets:
RAPID COMMUNICATIONS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7474472/
https://ncbi.nlm.nih.gov/pubmed/32468956
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.20.00793
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires